By THE ASSOCIATED PRESSOCT. 2, 2015
Federal health officials on Friday expanded approval of an innovative Merck drug to treat patients with an advanced form of the most common lung cancer. The Food and Drug Administration approved the drug, Keytruda, for advanced nonsmall cell lung cancer patients whose tumors have spread after taking other therapies. The disease accounts for roughly seven out of eight cases of lung cancer. Regulators approved Keytruda in 2014 to treat melanoma, the deadliest form of skin cancer. Keytruda is part of a promising new class of drugs called immunotherapies, which harness the body’s immune system to help fight cancer. Like many new cancer drugs, Keytruda is expensive at $12,500 per month, or $150,000 for a year’s supply. Bristol-Myers Squibb won approval for a similar indication for its Opdivo drug, in March.A version of this brief appears in print on October 3, 2015, on Page B2 of the New York edition with the headline: U.S. Expands Approval of Merck Lung Cancer Drug .  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.